Inside the research
Acadia Healthcare Company, Inc.
ACHC Research profile · latest available data
Price overview
$28.09
▲ +0.29 (+1.0%)
| 52w hi | $35.61 |
|---|---|
| 52w lo | $11.68 |
| Vol | 1.15M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.10
| Short | +0.25 |
|---|---|
| Medium | -0.05 |
| Long | -0.90 |
computed 2026-09-27
Key fundamentals
Acadia Healthcare Company, Inc.
Healthcare · Medical Care Facilities
| Market cap | $2.62B |
|---|---|
| Enterprise value | $5.24B |
| Forward P/E | 15.21x |
| EV / EBITDA | 9.80x |
| P / S (ttm) | 0.78x |
| Profit margin | -33.4% |
| Return on equity | -41.4% |
| Revenue growth | -0.4% |
| Earnings growth | -63.6% |
| Debt / equity | 118.06 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.25 | |
| Sector | +0.08 | |
| Technical | +0.11 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilities and eating disorder facilities; comprehensive treatment centers; and residential treatment centers, as well as facilities providing outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Risk Metrics
| Beta vs SPX | 0.84 |
|---|---|
| Corr SPX | 0.21 |
| Annual vol | 63.1% |
| Annual ret | -29.6% |
| Sharpe | -0.47 |
| Max DD | -84.8% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $28.46 |
|---|---|
| High / Low | $39.00 / $13.00 |
| Median | $30.00 |
| Analysts | 14 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 6 | |
| Hold | 6 | |
| Sell | 0 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-05-04 | RBC Capital | → Outperform |
| 2026-05-04 | Guggenheim | → Buy |
| 2026-05-01 | Cantor Fitzgerald | → Neutral |
| 2026-05-01 | Barclays | → Equal-Weight |
| 2026-04-28 | TD Cowen | → Buy |
| 2026-04-17 | UBS | → Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-28 | Earnings Release, Reg FD Disclosure… | read |
| 2026-05-18 | Other Material Event | read |
| 2026-05-06 | Shareholder Vote, Exhibits | read |
| 2026-04-29 | Earnings Release, Reg FD Disclosure… | read |
| 2026-04-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-03-12 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-25 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-23 | Officer / Director Change, Exhibits | read |
| 2026-01-20 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-01-13 | Earnings Release, Reg FD Disclosure… | read |
| 2025-12-02 | Reg FD Disclosure, Exhibits | read |
| 2025-11-10 | Reg FD Disclosure, Exhibits | read |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.93B | +21.1% | |
| Operating income | $604.36M | +49.5% | |
| Net income | -$21.67M | +51.1% | |
| Cash from ops | $131.90M | +26.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $27.85 | $28.38 | $27.43 | $28.09 | 1.15M |
| Sep 24 | $28.52 | $28.65 | $27.31 | $27.80 | 2.18M |
| Sep 23 | $29.41 | $29.78 | $28.09 | $28.51 | 2.46M |
| Sep 22 | $28.63 | $29.69 | $28.55 | $29.37 | 2.06M |
| Sep 21 | $28.33 | $29.14 | $28.31 | $28.37 | 1.49M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →